Asset profile
BCD-281
Monoclonal antibody
Evidence outlook · registrational
Multiple Sclerosis: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-12.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
51 competitors in this universe: 8 direct rivals (same mechanism and indication), 7 same-class, 36 same-indication; 29 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| BCD-281: this drug | Phase 3 | Monoclonal antibody | CD20 | ||
| Ocrelizumab | Approved | Monoclonal antibody | CD20 | ||
| Ocrevus Zunovo | Approved | Monoclonal antibody | CD20 | ||
| Ofatumumab | Approved | Monoclonal antibody | CD20 | ||
| Ublituximab | Approved | Monoclonal antibody | CD20 | ||
| ABP 692 | Phase 3 | Monoclonal antibody | CD20 | ||
| BCD-132 | Phase 3 | Monoclonal antibody | CD20 | ||
| CT-P53 | Phase 3 | Monoclonal antibody | CD20 | ||
| Divozilimab | Phase 3 | Monoclonal antibody | CD20 | ||
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | ||
| Rituximab | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | ||
| Acellbia | Phase 3 | Monoclonal antibody | CD20 | ||
| CT-P10 | Phase 3 | Monoclonal antibody | CD20 | ||
| HLX01 | Phase 3 | Monoclonal antibody | CD20 | ||
| MIL62 | Phase 3 | Monoclonal antibody | CD20 | ||
| SAR448501 | Phase 1 | Multispecific antibody | CD20 |
…and 36 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.